Mirati’s drug sitravatinib fails PhIII trial in combo with Opdivo for certain lung cancer

Mirati Therapeutics’ path to a second drug approval will likely have to wait. The San Diego biotech company said Wednesday that its investigational lung cancer drug failed a Phase III trial testing it in combination with Bristol Myers Squibb’s Opdivo. The drug, sitravatinib, and Opdivo weren’t better than the chemo…

Click here to view original post